A 3-month safety and efficacy study of travoprost 0.004% ophthalmic solution compared with timolol in pediatric patients with glaucoma or ocular hypertension

Dixon, El Roy; Landry, Theresa; Venkataraman, Srividhya; Gustafson, Nancy; Salem, C.; Bradfield, Yasmin S.; Aljasim, Leyla Ali; Feldman, Robert M.

doi:10.1016/j.jaapos.2017.07.202

Cited by 13 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…So, it seems that PGAs have better tolerance than beta blockers. Indeed, a similar conclusion was given in pediatric patients with glaucoma or ocular hypertension [69].…”

Section: Dry Eye Diseasesupporting

confidence: 62%

Ocular Surface Changes in Prostaglandin Analogue-Treated Patients

Shen

Huang

Yang

2019

Journal of Ophthalmology

View full text Add to dashboard Cite

Glaucoma is the second leading cause of blindness globally. Reducing intraocular pressure (IOP) has been acknowledged to be the main therapy for glaucoma. Prostaglandin analogues (PGAs) have become the first-line therapy for patients with glaucoma due to their powerful efficacy for lowering (IOP). However, usage of PGAs can also cause several notable side effects, including the changes in ocular surface. The relationship between PGAs and ocular surface changes is complicated and still remains unclear. In the present review, we summarize the recent studies of the effects of PGAs on ocular changes as well as the possible mechanisms that might provide new considerations during clinical medication.

show abstract

“…So, it seems that PGAs have better tolerance than beta blockers. Indeed, a similar conclusion was given in pediatric patients with glaucoma or ocular hypertension [69].…”

Section: Dry Eye Diseasesupporting

confidence: 62%

Ocular Surface Changes in Prostaglandin Analogue-Treated Patients

Shen

Huang

Yang

2019

Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…Similarly, in a study of adults with AA, only one of 26 patients experienced partial regrowth following latanoprost use 67 . A similar compound, travoprost, has reportedly caused an AE of trichomegaly in pediatric and adult patients with glaucoma 68,69 …”

Section: Resultsmentioning

confidence: 92%

Eyelash trichomegaly: a systematic review of acquired and congenital aetiologies of lengthened lashes

Hutchison

Duffens

Yale

et al. 2021

Acad Dermatol Venereol

View full text Add to dashboard Cite

Long eyelashes have been popularized and many commercially available products exist to achieve eyelash growth as a desired cosmetic effect. Eyelash trichomegaly may be induced by medications, procedures, or be related to medical conditions; however, the exact mechanisms that govern eyelash growth are not well elucidated. This study aims to identify and summarize aetiologies associated with eyelash trichomegaly. We report a systematic review of 148 clinical trials, prospective and retrospective studies, and case reports describing all evidence‐based potential aetiologies of eyelash trichomegaly obtained from the Medline/PubMed and Cochrane Library through January 2021. Inclusion criteria were defined as (i) human studies involving congenital and acquired diseases in which eyelash trichomegaly is a characteristic or (ii) assessment of trichomegaly as an adverse or desired effect of a medication or procedure. Exclusion criteria included: animal studies, articles not available in English, outcomes unrelated to eyelash trichomegaly, and secondary review articles. Pharmacologic agents associated with eyelash trichomegaly included prostaglandin analogues (15‐keto fluprostenol isopropyl ester, bimatoprost, latanoprost, and travoprost), epidermal growth factor receptor inhibitors (cetuximab, erlotinib, and panitumumab), interferon‐alpha, and calcineurin inhibitors (tacrolimus and cyclosporine). Surgical procedures of the eyelid, as well as allergic rhinitis, atopic dermatitis, HIV, ichthyosis vulgaris (IV), uveitis, and vernal keratoconjunctivitis were also associated with increased eyelash growth. Congenital disorders associated with lengthened eyelashes included Cantú syndrome, CHOPS syndrome, Coffin–Siris syndrome, congenital heart disease, Cornelia de Lange syndrome, Costello syndrome, familial trichomegaly, Floating Harbor syndrome, Hermansky–Pudlak syndrome, Kabuki–Makeup syndrome, KBG syndrome, Oliver–McFarlane syndrome, Rubinstein–Taybi syndrome, and Smith–Magenis syndrome. While the most common cause of eyelash trichomegaly is topical bimatoprost use, better understanding of pathways implicated in eyelash trichomegaly may lead to the discovery of additional medications to stimulate eyelash growth and create avenues for future therapeutic interventions.

show abstract

“…Out of the 157 patients included in the study (mean age 9.6 years), 77 received travoprost and 75 timolol; the patients were evaluated at 2 weeks, 6 weeks, and 3 months after treatment. The efficacy of both drugs showed to be comparable, with a mean IOP drop of −5.4 mmHg for travoprost and − 5.3 mmHg for timolol [132,133].…”

Section: Prostaglandin Analoguesmentioning

confidence: 92%

Childhood Glaucoma and Medical Treatment: An Up to Date

Greco¹,

Leto²,

Greco³

et al. 2022

Vision Correction and Eye Surgery

View full text Add to dashboard Cite

Successful treatment of paediatric glaucoma presents many challenges, with IOP control as the first but not the only priority. In paediatric cases medical therapy may play different roles: it could be an important resource for preparing patients for surgical intervention through clearing cornea, it may help control IOP post-operatively or it may be the initial and often the mainstay pillar for clinical management. Besides inadequate IOP reduction, multiple factors conspire against the success of long term medical therapy in paediatric glaucoma: the difficulties with long term adherence, more than in adults, adequate ascertainment of drug-induced side effects and potential adverse systemic effect of protracted therapy among others. Many medications are available for glaucoma management but many of them still carry a warning that “safety and efficacy in paediatric patients have not been established”. An “Up to date” of medical options for childhood glaucoma is the core aim of this chapter, hoping it could be useful for the daily clinical decision process.

show abstract

A 3-month safety and efficacy study of travoprost 0.004% ophthalmic solution compared with timolol in pediatric patients with glaucoma or ocular hypertension

Abstract: This study found travoprost to be noninferior to timolol in lowering IOP in patients with pediatric glaucoma or ocular hypertension. Travoprost was well-tolerated, and no treatment-related systemic adverse events were reported.

Cited by 13 publications

References 15 publications

Ocular Surface Changes in Prostaglandin Analogue-Treated Patients

Ocular Surface Changes in Prostaglandin Analogue-Treated Patients

Eyelash trichomegaly: a systematic review of acquired and congenital aetiologies of lengthened lashes

Childhood Glaucoma and Medical Treatment: An Up to Date

Contact Info

Product

Resources

About